With the intensification of population aging in China, the rise in the incidence of chronic diseases, and the enhancement of residents' health awareness, the demand for pharmaceuticals continues to grow. In recent years, the state has introduced a series of policies, including centralized volume-based procurement of drugs, dynamic adjustment of medical insurance catalogs, and consistency evaluation, aiming to promote high-quality development in the pharmaceutical industry, encourage the research and development of innovative drugs, reduce the medication burden on patients, and improve drug accessibility.
In the cardiovascular disease treatment drug market, the demand for antihypertensive drugs is steadily increasing, with compound preparations and new sustained-release formulations becoming future development directions. In the mental disorder treatment drug market, the usage rate of antidepressants is gradually rising, with new antidepressants emerging continuously. The organ transplantation immunosuppressant market has expanded with the increase in transplantation surgeries, and the research and application of new immunosuppressants are attracting attention. In the autoimmune disease treatment drug market, the market share of biologics and targeted small molecule drugs is gradually rising, providing patients with more options. In the future, the Chinese pharmaceutical market will continue to develop in the direction of innovation and high quality under policy guidance to meet the growing health needs of the people. For this reason, based on research into this market, Frost & Sullivan (Frost & Sullivan) has released an independent research report titled 'The Chinese Pharmaceutical Market'.
If you have further research needs on the Chinese pharmaceutical market, please contact us:
Mr. Mao from Frost & Sullivan
Tel: (+86) 159-2139-6033
E-mail: fred.mao@frostchina.com
Click on the link below to view a selected report:
